107947-17-1

Basic information

• Product Name: methyl 3-bromo-4-chlorobenzoate
• Synonyms: methyl 3-bromo-4-chlorobenzoate;3-Bromo-4-chlorobenzoic acid methyl ester;Benzoic acid, 3-broMo-4-chloro-, Methyl ester
• CAS NO: 107947-17-1
• Molecular Formula: C₈H₆BrClO₂
• Molecular Weight: 249.48904
• Mol File: 107947-17-1.mol

Chemical Properties

• Boiling Point: 280℃
• Flash Point: 123℃
• Appearance: /
• Density: 1.604
• Storage Temp.: Room temperature.
• CAS DataBase Reference: methyl 3-bromo-4-chlorobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl 3-bromo-4-chlorobenzoate(107947-17-1)
• EPA Substance Registry System: methyl 3-bromo-4-chlorobenzoate(107947-17-1)

Safety Data

• Hazardous Substances Data: 107947-17-1(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Methyl 3-bromo-4-chlorobenzoate is used as a key intermediate in the synthesis of various organic compounds, including pharmaceuticals, agrochemicals, and specialty chemicals. Its reactivity and structural features make it a versatile building block for the development of new molecules with desired properties.
Used in Pharmaceutical Industry:
Methyl 3-bromo-4-chlorobenzoate is used as a starting material for the synthesis of various pharmaceutical compounds, particularly those with anti-inflammatory, analgesic, or antipyretic properties. Its unique structure allows for the development of new drugs with improved efficacy and reduced side effects.
Used in Agrochemical Industry:
Methyl 3-bromo-4-chlorobenzoate is used as a precursor in the production of agrochemicals, such as herbicides, insecticides, and fungicides. Its reactivity and structural features enable the creation of new compounds with enhanced pest control properties and reduced environmental impact.
Used in Specialty Chemicals:
Methyl 3-bromo-4-chlorobenzoate is used as a raw material in the production of specialty chemicals, such as dyes, pigments, and polymers. Its unique properties allow for the development of new materials with improved performance characteristics and applications in various industries, including textiles, plastics, and coatings.

Upstream product

• 1126-46-1 Methyl 4-chlorobenzoate 
• 42860-10-6 3-bromo-4-chlorobenzoic acid 
• 75-36-5 acetyl chloride 
• 4731-65-1 tris(o-methoxyphenyl)phosphine 
• 67-56-1 methanol 

Downstream Products

• 329218-12-4 3-bromo-4-chloro-benzyl alcohol 
• 1429617-96-8 methyl 4-chloro-3-ethynylbenzoate 
• 1429617-94-6 4-chloro-3-((trimethylsilyl)ethynyl)benzoic acid methyl ester 
• 1253291-15-4 2-[4-chloro-3-(pyridin-2-ylethynyl)benzoyl]-1,2,3,4-tetrahydroisoquinoline hydrochloride 
• 1253291-13-2 2-[4-chloro-3-(pyridin-2-ylethynyl)benzoyl]isoindoline hydrochloride 
• 1197358-18-1 1-[4-chloro-3-(pyridin-2-ylethynyl)benzoyl]-4-pyridin-2-ylpiperazine 
• 1197358-00-1 4-chloro-3-(pyridin-2-ylethynyl)benzoic acid 
• 1073543-82-4 3-(3-(((6-cyclopropyl-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methyl)oxy)phenyl)propanoic acid 
• 1073545-47-7 methyl 6-cyclopropyl-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-carboxylate 
• 1073545-49-9 (6-cyclopropyl-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl-3-yl)methanol 
• 1073545-51-3 3-(chloromethyl)-6-cyclopropyl-2'-fluoro-5'-(methyloxy)-1,1'-biphenyl 
• 1070890-30-0 4-chloro-N-cyclopropyl-3-(3,5-dichloro-pyridin-2-yl)-N-(2-methoxy-phenyl)-benzamide 
• 1070890-31-1 4-chloro-3-(3,5-dichloro-pyridin-2-yl)-N-(2-hydroxy-phenyl)-N-methyl-benzamide 
• 1070892-47-5 4-chloro-3-(3,5-dichloro-pyridin-2-yl)-benzoic acid 

Relevant articles and documents

Alkynyl-substituted heterocyclic compound, preparation method therefor and medical use therefor for effectively treating and/or preventing FGFR-related diseases such as tumors

The present invention relates to an alkynyl-substituted heterocyclic compound serving as an FGFR inhibitor, a preparation method therefor and a medical use therefor. In particular, the present invention relates to a compound represented by the general formula (I) and its pharmaceutically acceptable salt, a pharmaceutical composition including the compound or its pharmaceutically acceptable salt, a method for treating and/or preventing FGFR-related diseases, particularly tumors, by using the compound or its pharmaceutically acceptable salt, and a preparation method of the compound or its pharmaceutically acceptable salt. The present invention also relates to an use of the compound or its pharmaceutically acceptable salt, or an pharmaceutical composition including the compound or its pharmaceutically acceptable salt in the preparation of a drug for treating and/or preventing FGFR-related diseases, particularly tumors, wherein the definition of each substituent in the general formula (I) is the same as that in the specification.

ALKYNYL-SUBSTITUTED HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

The present invention relates to an alkynyl-substituted heterocyclic compound acting as an FGFR inhibitor, a preparation method therefor and a medical use thereof. In particular, the present invention relates to a compound as shown in general formula (I) and a pharmaceutically acceptable salt thereof; a pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof; a method for treating and/or preventing FGFR-associated diseases, particularly tumors, by using the compound or a pharmaceutically acceptable salt thereof; and a preparation method for the compound or a pharmaceutically acceptable salt thereof. The present invention also relates to the use of the compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition including the compound or a pharmaceutically acceptable salt thereof in the preparation of a drug for treating and/or preventing FGFR-associated diseases, particularly tumors, wherein the definition of each substituent group in general formula (I) is the same as that in the description.

Rhodium-Catalyzed Double Alkyl-Oxygen Bond Cleavage: An Alkyl Transfer Reaction from Bis/Tris(o-alkyloxyphenyl)phosphine to Aryl Acids

An unprecedented rhodium-catalyzed selective cleavage of double alkyl-oxygen bonds of bis/tris(o-alkyloxyphenyl)phosphine has been realized, in which P atom functions as a directing group and simple aryl acids are the methyl group acceptor to provide methyl esters and a quaternary phosphonium salt. The preliminary mechanism was investigated via an 18O labeling experiment and stoichiometric reaction between a Rh-A crystal and an aromatic acid.

High-throughput virtual screening identifies novel N ′-(1- phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors

Lysine specific demethylase 1 (LSD1) plays an important role in regulating histone lysine methylation at residues K4 and K9 on histone H3 and is an attractive therapeutic target in multiple malignancies. Here we report a structure-based virtual screen of

SUBSTITUTED (E)-N'-(1-PHENYLETHYLIDENE) BENZOHYDRAZIDE ANALOGS AS HISTONE DEMETHYLASE INHIITORS

In one aspect, the invention relates to substituted (E)-N'-(1- phenylethylidene)benzohydrazide analogs, derivatives thereof, and related compounds, which are useful as inhibitors of lysine-specific histone demethylase, including LSD1; synthetic methods fo

SUBSTITUTED BIPHENYL PHENOXY-, THIOPHENYL- AND AMINOPHENYLPROPANOIC ACID GPR40 MODULATORS

The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula (I) where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.

GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO

GnRH receptor antagonists are disclosed which have utility in the treatment of a variety of sex-hormone related conditions in both men and women. The compounds of this invention have the structure, wherein R1a, R1b, R1c, R1d, R2, R2a, and A are as defined herein, including stereoisomers, esters, solvates and pharmaceutically acceptable salts thereof. Also disclosed are compositions containing a compound of this invention in combination with a pharmaceutically acceptable carrier, as well as methods relating to the use thereof for antagonizing gonadotropin-releasing hormone in a subject in need thereof.

Discovery of potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70

A series of 1,2,4-oxadiazole analogues has been shown to be potent and selective SH2 inhibitors of the tyrosine kinase ZAP-70, a potential therapeutic target for immune suppression. These compounds typically are 200- 400-fold more potent than the native,